<DOC>
	<DOCNO>NCT00674609</DOCNO>
	<brief_summary>The purpose study determine whether Sativex® GW-2000-02 effective management subject intractable cancer-related pain .</brief_summary>
	<brief_title>A Study Sativex® Pain Relief Patients With Advanced Malignancy</brief_title>
	<detailed_description>This two week ( two day baseline two week treatment period ) , multicentre , double blind , randomise , placebo control , parallel group study evaluate efficacy Sativex® GW-2000-02 subject cancer-related pain . Subjects screen determine eligibility complete two-day baseline period . Subjects return centre assessment , randomisation dose introduction . All subject allow continue use current medication , provide dose remain stable throughout study period . Their progress review seven 10 day end study ( day 14 20 ) , upon withdrawal . Subjects study give opportunity enrol open label extension study ( GWEXT0101 ) .</detailed_description>
	<criteria>Willing able give inform consent . Male female , age 18 year . Diagnosed cancer type , consider terminal . Diagnosed cancerrelated pain wholly alleviate current strong opioid treatment whose level pain measure NRS ³four least one occasion per day , two day runin period , lead visit 1 . On strong opioid maintenance therapy least seven day prior screen visit . Willing abstain use cannabis study , study medication . No cannabinoids use ( cannabis , Marinol® Nabilone ) least seven day Visit 1 willing abstain use cannabis study . Clinically acceptable blood result screen visit . Able ( investigator opinion ) willing undertake comply study requirement . Willing allow general practitioner , consultant appropriate , inform study participation . Willing Home Office notify participation study ( applicable UK centre ) . Know history substance misuse . Known suspected adverse reaction cannabinoids cause psychosis severe psychiatric illness . Received epidural analgesia within 48 hour prior study entry . Either receive , within two week study entry , due receive chemotherapy radiotherapy study . Unable give inform consent . History type schizophrenia , psychotic illness , serious personality disorder , significant psychiatric illness depression associate chronic pain and/or response underlie condition . Currently take levodopa ( Sinemet® , Sinemet plus® , Levodopa® , Ldopa® , Madopar® , Benserazide® ) . Had serious cardiovascular disorder , include angina , uncontrolled hypertension , uncontrolled symptomatic cardiac arrhythmia . Significant renal hepatic impairment , opinion investigator , unsuitable treatment study medication . History epilepsy . Had oral cavity cancer whose previous treatment include radiotherapy floor mouth . Female subject pregnant lactate childbearing potential inadequately protect conception study three month thereafter . Male subject sexually active use adequate form contraception study three month thereafter . Subjects participate clinical research study past four week , prior study entry . Planned travel outside UK study ( applicable UK centre ) . Subjects , opinion investigator , unsuitable participate study reason , mention entry criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Palliative Care</keyword>
	<keyword>Pain</keyword>
	<keyword>Cancer</keyword>
</DOC>